Leaders, Not Followers

The University of Kansas Cancer Center's comprehensive prostate cancer program is comprised of the nation’s leading experts. In fact, we’re the most subspecialized prostate cancer program in Kansas, Kansas City and the region. Our nationally ranked urology program offers patients and collaborating care teams the highest level of knowledge, expertise and multidisciplinary care that comes from being an/a:

Our multidisciplinary, fellowship-trained prostate cancer team includes subspecialized physicians that only focus on prostate cancer within their given fields:

• Urologic oncologists
• Radiation oncologists
• Medical oncologists
• Radiologists
• Pathologists

Every patient is different, not all prostate cancer is equal. As such, there’s no one-size-fits-all approach. Subspecialists who work day-in and day-out on prostate cancer have a deeper understanding of all available treatment options for a specific case. Prostate cancer treatment is often multimodal; a combination of surgery followed by radiation, for example. We know complexities of the disease that may be missed by a specialist, which in turn could limit treatment options. Our team works together to provide the best, most comprehensive diagnoses, treatments and care plans. 

As part of an academic medical center, we offer a comprehensive approach to prostate cancer care including the most innovative treatment options.

• Innovation in surgical oncology
  Our fellowship-trained surgical team approaches prostatectomy in a personalized manner, offering the complete range of surgical options including Retzius-sparing prostatectomy, nerve sparing procedures and extended pelvic lymph node dissections.
• Innovation in radiation oncology
  Our radiation oncology team offers the full range of radiation options including brachytherapy, SBRT and is the first in the region to offer proton therapy.
• Innovation in medical oncology
  Our prostate cancer focused medical oncology team offers access to new and advanced prostate cancer treatments. We are the first and only cancer center in the region to offer Pluvicto™ as a new targeted therapy for metastatic prostate cancer. It is the first FDA-approved targeted radioligand therapy available for PSMA-positive metastatic hormone-resistant (also known as castrate-resistant) prostate cancer.

Together, we ensure that the right plan is made for each patient.  Along with providing these advanced treatments, our physicians lead national and international clinical trials for early-stage, advanced and metastatic prostate cancer. We are at the forefront of clinical studies with immunotherapy and targeted therapy to treat prostate cancer.